单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
宫颈癌的过继性 TIL（肿瘤浸润淋巴细胞）细胞治疗
英文原题：Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer.
查看英文原题
Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
宫颈癌是女性最常见的恶性肿瘤之一。作为一种病毒相关癌症，宫颈癌在开发病毒靶向免疫治疗方面吸引了大量关注，包括疫苗和过继性免疫细胞治疗（ACT）。在一项初步临床试验中，过继性TIL（肿瘤浸润淋巴细胞）（TILs）细胞治疗已被发现能够控制部分已接受多线治疗的宫颈癌患者的晚期疾病进展。此外，在一些病例中已发现可持续的治疗效果。TIL治疗对患者的安全风险极小，或至少是可管理的。在本综述中，我们聚焦于TILs的多功能性，尝试总结提高TILs治疗效果的潜在策略并讨论相关前景。
展开英文摘要原文
Cervical cancer is one of the most common malignancies among females. As a virus-related cancer, cervical cancer has attracted a lot of attention to develop virus-targeted immune therapy, including vaccine and adoptive immune cell therapy (ACT). Adoptive tumor infiltrating lymphocytes (TILs) cell therapy has been found to be able to control advanced disease progression in some cervical cancer patients who have received several lines of treatment in a pilot clinical trial.
In addition, sustainable therapeutic effect has been identified in some cases. The safety risks of TIL therapy for patients are minimal or at least manageable. In this review, we focused on the versatility of TILs and tried to summarize potential strategies to improve the therapeutic effect of TILs and discuss related perspectives.
论文信息
- 作者
- Zhu Y、Zhou J、Zhu L、Hu W、Liu B、Xie L
- 单位
- The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, China.China
- 文献类型
- 综述
- 期刊
- Human vaccines & immunotherapeutics2022 Nov 30
- 原文标识
- PubMed 35468048 · DOI 10.1080/21645515.2022.2060019
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →